We also did not observe profound differences in the number of Ki67-positive cancer cells in vivo in response to doxorubicin/PARPi treatment, both in p66ShcA-null and p66ShcA-expressing Hs578T tumors (Supplemental Figure 6C). This evidence concerns the gene MKI67 and cancer.